The Claim
In a cohort of 312,097 individuals, genetically reduced PCSK9 function is not associated with an increased risk of type 2 diabetes, with no statistically significant association observed, suggesting that PCSK9 inhibition may not elevate diabetes risk as previously suggested by some studies.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People who naturally have lower activity of a protein called PCSK9 don’t seem to have a higher chance of getting type 2 diabetes — which means drugs that target PCSK9 might not increase diabetes risk like some earlier studies worried they would.
See the scientific wording
Genetically reduced PCSK9 function is not associated with increased risk of type 2 diabetes in a cohort of 312,097 individuals, with no statistically significant association observed, contrasting with some prior studies and suggesting that PCSK9 inhibition may not elevate diabetes risk as previously feared.
What the research says
1 studyThe study looked at people with natural changes in the PCSK9 gene and found no increased risk of type 2 diabetes, which supports the idea that lowering PCSK9 doesn’t raise diabetes risk.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.